AMERICAN ACADEMY OF NEUROLOGY for AMERICAN ACADEMY OF NEUROLOGY
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R. 88; Section 505: Repeal of Unrelated Business Income Tax on Qualified Transportation Fringe Benefits
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEREK CHRISTOPHER BRANDT | — |
Veterans VET
Strengthening the VA Centers of Excellence
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEREK CHRISTOPHER BRANDT | — |
Health Issues HCR
S. 1384/ H.R. 3805: Prescription Drug Rebate Reform Act of 2019; all provisions. S. 1391 / H.R. 2296: FAIR Accountability and Innovative Research Drug Pricing Act; all provisions. S. 2387: We Protect American Investment in Drugs (PAID) Act; all provisions. S.2443: Investment in Tomorrow's Pediatric Health Care Workforce Act; all provisions. S. 2546 / H.R. 2279: Safe Step Act; all provisions. H.R. 1865: Further Consolidated Appropriations Act, 2020; priorities within this package around outlined below. H.R. 2781: Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act, section 4. H.R. 3030: Patient-Centered Outcomes Research Extension Act of 2019; all provisions. H.R. 3439: Protecting Access to Information for Effective and Necessary Treatment (PATIENTS) Act of 2019; all provisions. H.R. 3502, Protecting People from Surprise Medical Bills Act; all provisions. Supporting policies to address prescription drug costs, including improving drug pricing transparency and eliminating or reducing direct-to-consumer advertising. Funding for the National Neurological Conditions Surveillance System and opposing certain expansions to this program. Research into firearm morbidity and mortality prevention at CDC, fetal tissue research, and the NIH including the BRAIN Initiative. Funding for Congressionally Directed Medical Research Programs at the DoD. Lifting the federal ban restricting HHS from studying a Universal Patient Identifier. Policy to address surprise medical billing. Promoting interoperability in electronic health records
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEREK CHRISTOPHER BRANDT | — |
| MATTHEW ROSS KERSCHNER | — |
| MICHAEL LISOWSKI New | Senior Legislative Assistant, Rep. Joe Heck. |
Medicare/Medicaid MMM
S. 2543: Prescription Drug Pricing Reduction Act; sections 102, 107, 110, 121, 128, 141. H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; all provisions. H.R. 3107: Improving Seniors' Timely Access to Care Act of 2019; all provisions. H.R.4945: Safeguarding Medicare Access to Respiratory Therapy Act of 2019; all provisions. Supporting CMSs final rule on Evaluation and Management (E/M) billing codes. Recommending various changes to the CMS proposed rule on long-term electroencephalogram (EEG) billing codes. Supporting policies to address prescription drug costs, including supporting direct negotiation in Medicare, improving drug pricing transparency, extending negotiated Rx discounts to be passed through to patients cost-sharing requirements, and capping beneficiary out-of-pocket costs in Medicare Part D. Issues associated with Qualified Clinical Data Registry implementation, measures, and interoperability. Improvements to the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015. Medicare coverage of oxygen therapy for cluster headaches. Advocating for reform to stark and anti-kickback laws to promote value-based payment arrangements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEREK CHRISTOPHER BRANDT | — |
| MATTHEW ROSS KERSCHNER | — |
| MICHAEL LISOWSKI New | Senior Legislative Assistant, Rep. Joe Heck. |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.